01—Abstract
Summary
Summary of the 10-K filed February 28, 1996. Cited figures are marked; the original filing is the authoritative source.
Important note: the filing provided is Schering-Plough Corporation's (not Merck & Co.'s) Form 10-K for fiscal 1995, filed February 28, 1996.
The analysis below is based on the Schering-Plough document. Schering-Plough had a strong 1995. Sales rose 13% to $5.10 billiona, driven mainly by CLARITIN (worldwide sales of $789 million, up from $505 million) and the respiratory franchise, which grew 29% domestically.
Income from continuing operations rose 14% to $1.05 billionb, and EPS from continuing operations was $2.85, up 18%, helped by share repurchases. Reported net income was $886.6 million ($2.40 per share), reduced by a $156.2 million after-tax loss on the June 1995 sale of the contact lens business, which was treated as a discontinued operation. The main risks are product concentration and generic competition.
PROVENTIL (albuterol) sales of $422 millionc are expected to decline as a generic metered-dose inhaler was approved in December 1995 and Warrick Pharmaceuticals launched its own version. THEO-DUR also faced generic pressure, and INTRON A sales in Japan fell to $94 million from $141 million, as Japanese health authorities worked to control costs. Litigation exposure is significant but management considers material loss remote: more than 150 antitrust suits by pharmacies and consumers (a $22.1 million federal class settlement is pending court approval), more than 95 estrogen-related product liability suits claiming over $2 billion, and a $63.6 million THEO-DUR judgment under appeal.
Financially, the company is in solid shape. Operating cash flow was $1.38 billiond, capital expenditures were $293.8 million, and the company repurchased 9.9 million shares for $493.8 million. The dividend rose to $1.125 per share from $0.99, and the debt-to-capital ratio fell to 36% from 38%.
Debt is modest, with total long-term debt of $87.1 million and short-term borrowings of $841.3 million, and the company held A-1+/P-1 commercial paper ratings and AA/Aa3 bond ratings. R&D spending was $656.9 million, or 12.9% of sales.
02—Key points
Key Highlights
- Net sales rose 13% to $5,104.4 million in 1995, with volume growth of 10% and favorable currency effects of 3%.
- Income from continuing operations rose 14% to $1,053.0 million; EPS from continuing operations was $2.85, up 18%, aided by share buybacks.
- Net income was $886.6 million ($2.40 per share) after a $156.2 million loss on disposal of the contact lens business, sold in June 1995.
- CLARITIN franchise sales reached $789 million (vs. $505 million in 1994), and respiratory product sales grew 29% in the U.S.
- PROVENTIL faces generic erosion after a generic albuterol metered-dose inhaler was approved in December 1995; THEO-DUR also faces generic competition.
- Operating cash flow was $1,383.3 million; the company repurchased 9.9 million shares for $493.8 million and raised its quarterly dividend to $0.29.
- Legal exposure includes more than 150 antitrust suits (a $22.1 million federal class settlement is pending approval), more than 95 estrogen-related suits claiming over $2 billion, and a $63.6 million THEO-DUR judgment under appeal.
03—Questions
Frequently Asked Questions
Is this filing from Merck & Co., and what company does it actually describe?
No. The document is the Form 10-K of Schering-Plough Corporation (Madison, New Jersey) for fiscal 1995, not Merck & Co. (MRK). Investors should verify the company identity before relying on this analysis.
What drove 1995 revenue growth?
Sales rose 13% to $5.10 billion. Growth came mainly from the CLARITIN brand, the VANCENASE and VANCERIL respiratory lines, IMDUR and K-DUR in cardiovascular, and EULEXIN and CEDAX in anti-infective and anticancer products. Favorable foreign exchange added about 3 percentage points.
How much did the contact lens divestiture affect results?
The June 1995 sale of the contact lens business produced a $156.2 million after-tax loss on disposal ($0.42 per share), which reduced reported net income to $886.6 million from income from continuing operations of $1,053.0 million. Proceeds from the sale were $47.5 million.
What are the main risks to future earnings?
Key risks include generic competition for PROVENTIL and THEO-DUR, falling INTRON A sales in Japan, increasingly competitive U.S. pricing from managed care and government payers, international cost-containment programs, and a potential stronger U.S. dollar, which management says would hurt 1996 sales and earnings. Major litigation, including antitrust and estrogen-related product liability suits, also poses risk, though management considers material losses beyond accruals remote.
How is the company returning capital and how strong is its balance sheet?
In 1995 the company repurchased 9.9 million shares for $493.8 million, paid $416.4 million in dividends ($1.125 per share, up from $0.99), and cut its debt-to-capital ratio to 36% from 38%. It had $822.6 million in unused credit lines and held A-1+/P-1 commercial paper and AA/Aa3 bond ratings at year-end 1995.
04—Continue